Menorrhagia Drug Pipeline Analysis Report 2025

Menorrhagia, or heavy menstrual bleeding (HMB), is a condition characterized by excessive bleeding during menstruation. It affects approximately 37% of female adolescents, presenting a significant clinical challenge. There is a high unmet need for improved therapies, as current treatments such as hormonal therapy and nonsteroidal anti-inflammatory drugs (NSAIDs) are often insufficient. The growing focus on innovative menorrhagia therapeutic products is expected to support pipeline growth in the coming years. These advancements aim to address the limitations of existing treatments and offer more effective solutions for managing this widespread condition.

Report Coverage

The Menorrhagia Drug Pipeline Insight Report by the publisher gives comprehensive insights into menorrhagia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for menorrhagia. The menorrhagia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The menorrhagia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with menorrhagia treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to menorrhagia.

Menorrhagia Drug Pipeline Outlook

Menorrhagia is characterized by abnormally heavy or prolonged menstrual bleeding. It can occur due to various factors, including hormonal imbalances, uterine fibroids, endometriosis, or bleeding disorders. Excessive bleeding can interfere with daily activities and lead to anemia.

Menorrhagia treatment focuses on reducing bleeding and managing underlying causes. Options include hormonal therapies (such as birth control), NSAIDs, tranexamic acid, and in severe cases, surgical interventions like endometrial ablation or hysterectomy. These treatments aim to alleviate symptoms and improve quality of life.

Menorrhagia Epidemiology

Menorrhagia, affecting 37% of female adolescents, presents a significant global health burden. It impacts over 10 million American women annually, with 1 in 5 women experiencing heavy menstrual bleeding. In Japan, 19% of women aged 15-49 report heavy menstrual bleeding. The rising incidence reflects the urgent need for effective therapies, fostering growth in the menorrhagia drug pipeline.

Menorrhagia Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of menorrhagia drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Peptides
• Gene Therapies
• Hormonal Drugs

By Route of Administration

• Oral
• Parenteral
• Others

Menorrhagia - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total menorrhagia clinical trials.

Menorrhagia Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the menorrhagia pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, and hormonal drugs. The menorrhagia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for menorrhagia.

Menorrhagia Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the menorrhagia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed menorrhagia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in menorrhagia clinical trials:

• Jiangsu HengRui Medicine Co., Ltd.
• Qilu Pharmaceutical Co., Ltd.
• Bio Genuine Biotech Co., Ltd.
• Kissei Pharmaceutical Co., Ltd.
• Myovant Sciences GmbH
• AMAG Pharmaceuticals, Inc.
• Macleods Pharmaceuticals Limited

Menorrhagia Emerging Drugs Profile

This section provides a detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for menorrhagia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of menorrhagia drug candidates.

Drug: Relugolix

The drug Relugolix, sponsored by Qilu Pharmaceutical Co., Ltd., is being tested in a Phase III clinical trial aimed at evaluating its efficacy and safety in women with heavy menstrual bleeding associated with uterine fibroids. The study will involve approximately 120 participants and is expected to be completed by February 2027. The objective of the clinical study is to determine the benefits of Relugolix compared to a placebo.

Drug: BG2109

The Phase III study, sponsored by Bio Genuine (Shanghai) Biotech Co., Ltd., aims to evaluate the efficacy and safety of BG2109 in treating heavy menstrual bleeding associated with uterine fibroids. The trial will assess BG2109 alone and in combination with add-back therapy. The study is expected to conclude by March 2025, enrolling about 312 participants.

Drug: SHR7280 Tablets

Jiangsu HengRui Medicine Co., Ltd., is sponsoring a Phase II/III study, that aims to evaluate the efficacy and safety of SHR7280 tablets in individuals with menorrhagia and uterine fibroids. The objective of this trial is to determine the optimal therapeutic dose of SHR7280 and assess its impact on reducing menstrual bleeding. The study is expected to conclude by June 2026, with an estimation of 357 participants.

Reasons To Buy This Report

The Menorrhagia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for menorrhagia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into menorrhagia collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Menorrhagia - Pipeline Insight Report

• Which companies/institutions are leading the menorrhagia drug development?
• What is the efficacy and safety profile of menorrhagia pipeline drugs?
• Which company is leading the menorrhagia pipeline development activities?
• What is the current menorrhagia commercial assessment?
• What are the opportunities and challenges present in the menorrhagia drug pipeline landscape?
• What is the efficacy and safety profile of menorrhagia pipeline drugs?
• Which company is conducting major trials for Menorrhagia drugs?
• Which companies/institutions are involved in menorrhagia collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in menorrhagia?

This product will be delivered within 3-5 business days.